Levy A - Search Results

1

[Cell cycle, mitosis and therapeutic applications].

Levy A, Albiges-Sauvin L, Massard C, Soria JC, Deutsch E. Levy A, et al. Bull Cancer. 2011 Oct;98(9):1037-45. doi: 10.1684/bdc.2011.1382. Bull Cancer. 2011. PMID: 21669563 Free article. Review. French.

2

[Everolimus (RAD001) and solid tumours: a 2008 summary].

Lévy A, Sauvin LA, Massard C, Soria JC. Lévy A, et al. Bull Cancer. 2008 Dec;95(12):1205-11. doi: 10.1684/bdc.2008.0767. Bull Cancer. 2008. PMID: 19091655 Free article. Review. French.

3

[Prognosis and predictive factors in prostate cancer].

Albiges-Sauvin L, Lévy A, Massard C, Fizazi K. Albiges-Sauvin L, et al. Among authors: levy a. Bull Cancer. 2009 Apr;96(4):439-49. doi: 10.1684/bdc.2009.0846. Bull Cancer. 2009. PMID: 19357018 Free article. Review. French.

4

[Molecular targeted therapies in small-cell lung cancer].

Levy A, Malouf GG, Besse B, Massard C, Soria JC. Levy A, et al. Bull Cancer. 2010 May;97(5):535-45. doi: 10.1684/bdc.2010.1035. Bull Cancer. 2010. PMID: 20093224 Free article. Review. French.

5

Can a cure be achieved with taxane-based chemotherapy plus surgery in patients with primary mediastinal non-seminomatous germ cell tumors and progression or relapse despite first-line chemotherapy?

Miskovska V, Levy A, Massard CC, Gross-Goupil M, Bossi A, Fizazi K. Miskovska V, et al. Among authors: levy a. Onkologie. 2010;33(3):119-20. doi: 10.1159/000277824. Epub 2010 Feb 22. Onkologie. 2010. PMID: 20215805 Free article. Clinical Trial.

6

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X. Postel-Vinay S, et al. Among authors: levy a. J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444876

7

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Ederhy S, Bahleda R, Gomez-Roca C, Chargari C, Brocheriou-Spelle I, Soria JC. Levy A, et al. Invest New Drugs. 2012 Jun;30(3):1116-20. doi: 10.1007/s10637-011-9671-z. Epub 2011 Apr 21. Invest New Drugs. 2012. PMID: 21509469 Clinical Trial.

8

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

Bourgier C, Levy A, Vozenin MC, Deutsch E. Bourgier C, et al. Among authors: levy a. Cancer Metastasis Rev. 2012 Dec;31(3-4):699-712. doi: 10.1007/s10555-012-9381-9. Cancer Metastasis Rev. 2012. PMID: 22706781 Review.

9

FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.

Levy A, Chargari C, Huguet F, Védrine L, Deutsch E. Levy A, et al. Pancreas. 2012 Aug;41(6):973-4. doi: 10.1097/MPA.0b013e3182496e90. Pancreas. 2012. PMID: 22781912 No abstract available.

10

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

Guillot A, Levy A, Pacaut C, Collard O, Massard C, Merrouche Y, Magné N. Guillot A, et al. Among authors: levy a. Clin Genitourin Cancer. 2012 Sep;10(3):147-52. doi: 10.1016/j.clgc.2012.05.002. Epub 2012 Jul 15. Clin Genitourin Cancer. 2012. PMID: 22796529 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,132 results

Search Page